Kyverna Therapeutics, Inc. Common Stock (KYTX) is a publicly traded Healthcare sector company. As of July 26, 2026, KYTX trades at $7.41 with a market cap of $450.49M and a P/E ratio of -2.04. KYTX moved +1.71% today. Year to date, KYTX is -21.17%; over the trailing twelve months it is +74.76%. Its 52-week range spans $1.78 to $13.67. Analyst consensus is strong buy with an average price target of $30.00. Rallies surfaces KYTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for KYTX, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $7.41 |
| Market Cap | $450.49M |
| P/E Ratio | -2.04 |
| EPS | $-3.64 |
| Dividend Yield | 0.00% |
| 52-Week High | $13.67 |
| 52-Week Low | $1.78 |
| Volume | 706.45K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-161.31M |
| Gross Margin | 0.00% |
5 analysts cover KYTX: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $30.00.